Enrollment is now open across all 38 clinical sites in the Phase 2b trial testing pirepemat  (previously known as IRL752), IRLAB Therapeutics’ investigational therapy intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. The Phase 2b trial (NCT05258071) is recruiting Parkinson’s…
A highly sensitive blood test accurately identified people with synucleinopathies, disorders caused by the abnormal aggregation of the protein alpha-synuclein, such as Parkinson’s disease. The test, called immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), detected early-formed alpha-synuclein fibrils — or seeds — that eventually grew into disease-causing aggregates. Microscopic analysis detected…
Alterity Therapeutics’ new Phase 2 clinical trial testing ATH434 in patients with multiple system atrophy (MSA), a form of atypical parkinsonism, has enrolled its first patient, the company announced. The open-label, biomarker ATH434-202 study (NCT05864365) is enrolling 15 adults, ages 30-75 years, with advanced MSA and…
Patterns of brain damage in Parkinson’s disease differ based on whether or not individuals have REM sleep behavior disorder (RBD), a new study suggests. Study findings indicate that patterns of brain damage are similar among Parkinson’s patients who develop RBD before or after Parkinson’s motor symptoms. Based on…
In people with Parkinson’s disease, sleep disturbances and excessive daytime sleepiness (EDS) were associated with the impairment of the autonomic nervous system that controls involuntary bodily functions, a study shows. Depression and rapid eye movement sleep behavior disorder (RBD), or dream-enacting behavior, also contributed to problems sleeping at night…
The first patient has been dosed in a Phase 2 trial testing BIA 28-6156, Bial’s investigational therapy for Parkinson’s disease patients with mutations in the glucocerebrosidase 1 (GBA1) gene. The ACTIVATE (NCT05819359) study is currently screening Parkinson’s patients, ages 35 to 80 years, across multiple sites in…
NurrOn Pharmaceuticals has partnered with South Korean HanAll Biopharma and Daewoong Pharmaceutical to continue developing its candidate therapy for Parkinson’s disease and other neurodegenerative disorders. A Phase 1 clinical trial of its lead oral investigational therapy ATH-399A is expected to start this year. Before testing it…
Long-term treatment with sargramostim, an immune-modulating medication from Partner Therapeutics, was safe and improved motor function for five men with Parkinson’s disease, according to data from a small open-label Phase 1 clinical trial. Evidence suggested the therapy exerted its benefits by boosting the function of anti-inflammatory…
The Michael J. Fox Foundation (MJFF) is partnering with H1 to enhance the connections between physicians, researchers and patients with Parkinson’s disease. MJFF will use H1’s Trial Landscape platform to identify and communicate with lead researchers and physicians treating Parkinson’s patients, including those in populations typically unrepresented…
A new digital tool called MAP DBS may help improve the efficiency of deep brain stimulation (DBS) for people with Parkinson’s disease, a new study suggests. “We showed that MAP DBS can improve the time spent at the initial DBS programming visit when compared to [standard-of-care] procedures, which has…
Get regular updates to your inbox.
